Page last updated: 2024-11-03

propranolol and Myalgia

propranolol has been researched along with Myalgia in 3 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Myalgia: Painful sensation in the muscles.

Research Excerpts

ExcerptRelevanceReference
"injection abolished carrageenan-evoked hyperalgesia at the doses, at which the drugs failed to alter the hypersensitivity when they were given alone."1.39Effects of a combination of ketanserin and propranolol on inflammatory hyperalgesia in rats. ( Hong, Y; Wang, D; Zhou, X, 2013)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Park, BD1
Lyn-Kew, K1
Granchelli, A1
Mehta, A1
Sanders, AE1
Slade, GD1
Fillingim, RB1
Ohrbach, R1
Arbes, SJ1
Tchivileva, IE1
Wang, D1
Zhou, X1
Hong, Y1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder[NCT02437383]Phase 2200 participants (Actual)Interventional2015-08-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Diastolic Blood Pressure After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm Hg (Least Squares Mean)
Propranolol ER-3.3
Placebo1.0

Change in Heart Rate After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionbeats per minute (Least Squares Mean)
Propranolol ER-3.9
Placebo1.5

Change in Maximum Assisted Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER-0.3
Placebo-0.8

Change in Maximum Unassisted Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER-0.9
Placebo-1.2

Change in Pain-free Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER4.5
Placebo1.4

Change in Pressure Pain Threshold at Lateral Epicondyle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of lateral epicondyle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER41.4
Placebo22.7

Change in Pressure Pain Threshold at Masseter Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of masseter muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/- 7)

InterventionkPa (Least Squares Mean)
Propranolol ER38.3
Placebo29.3

Change in Pressure Pain Threshold at Temporalis Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals (kPa), from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporalis muscle, are averaged to obtain a single pressure pain threshold value per anatomical site. The range is 0-500 kPa and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER41.8
Placebo38.4

Change in Pressure Pain Threshold at Temporomandibular Joint After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporomandibular joint, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER36.8
Placebo25.3

Change in Pressure Pain Threshold at Trapezius Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of trapezius muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER64.1
Placebo63.3

Change in Systolic Blood Pressure After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm Hg (Least Squares Mean)
Propranolol ER-3.6
Placebo1.3

Change in the Headache Impact Test (HIT-6) Global Score After 9 Weeks of Treatment

"The HIT-6 contains 6 items and assesses headache-related disability by the frequency of daily activity limitations ranging from never to always. The 6 item scores are summed to yield a global score ranging from 36 to 78. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-5.1
Placebo-3.1

Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Score After 9 Weeks of Treatment

"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.3
Placebo-0.7

Change in the Hospital Anxiety and Depression Scale (HADS) Depression Score After 9 Weeks of Treatment

"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.0
Placebo-0.6

Change in the Jaw Functional Limitation Scale (JFLS) Global Score After 9 Weeks of Treatment

"The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = no limitation and 10 = severe limitation. The Global Score is computed as the mean response for all items and ranges from 0 to 10. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.1
Placebo-0.8

Change in the Perceived Stress Scale (PSS) Global Score After 9 Weeks of Treatment

"The PSS assesses the frequency of 14 sources of stress on a scale from 0 = never to 4 = very often. The item scores are summed to yield a global score ranging from 0 to 56. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-2.6
Placebo-1.9

Change in the Pittsburgh Sleep Quality Index (PSQI) Global Score After 9 Weeks of Treatment

The PSQI has 19 items grouped into 7 component scores, each weighted equally on a 0-3 scale, The 7 component scores are summed to yield a global PSQI score, which has a range of 0-21. A higher score means a worse outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-0.7
Placebo-1.0

Change in the SF-12 Health Survey v2 (SF-12v2) Mental Component Summary (MCS) After 9 Weeks of Treatment

"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER3.6
Placebo2.8

Change in the SF-12 Health Survey v2 (SF-12v2) Physical Component Summary (PCS) After 9 Weeks of Treatment

"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER1.2
Placebo0.3

Change in the SF-McGill Pain Questionnaire Affective Component After 9 Weeks of Treatment

"The SF-McGill Pain Questionnaire contains 4 affective descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 12. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-2.9
Placebo-3.1

Change in the SF-McGill Pain Questionnaire Present Facial Pain Intensity After 9 Weeks of Treatment

"Self-reported present intensity of facial pain at the moment of assessment scored on a descriptive scale where 1 = no pain' and 6 = excruciating pain. A higher score means worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-0.9
Placebo-0.7

Change in the SF-McGill Pain Questionnaire Sensory Component After 9 Weeks of Treatment

"The SF-McGill Pain Questionnaire contains 11 sensory descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 33. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.9
Placebo-1.6

Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Duration After 9 Weeks of Treatment

"Self-reported average facial pain duration for the last week scored on 0-100 percentage scale where percent = percent of waking day you had facial pain. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-23.6
Placebo-21.6

Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Intensity After 9 Weeks of Treatment

"Self-reported average facial pain intensity for the last week scored on 0-100 numerical rating scale where 0 = no pain and 100 = the most intense pain imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-18.2
Placebo-15.8

Change in the SF-McGill Pain Questionnaire Weekly Fatigue After 9 Weeks of Treatment

"Self-reported average fatigue for the last week scored on 0-100 numerical rating scale where 0 = no fatigue and 100 = the greatest imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-12.0
Placebo-11.4

Change in the Symptom Checklist 90-Revised (SCL-90R) Somatization Scale Score After 9 Weeks of Treatment

"The SCL-90R Somatization Scale is a 12-item assessment of somatic symptom distress over the past 7 days rated from 0 = not at all to 4 = extremely. The scale score is computed as the mean for all items. The score range is from 0 to 4. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-0.2
Placebo-0.2

Change in the Weekly Mean Pain Duration After 9 Weeks of Treatment

"Weekly mean pain duration computed as the arithmetic mean of daily pain duration values during the week prior to randomization and prior to each study visit. Daily pain duration is measured on 0-100 percentage scale where percent = percent of waking day you had facial pain as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-17.9
Placebo-16.6

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary and divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-13.9
Placebo-12.1

Change in the Weekly Mean Pain Intensity After 9 Weeks of Treatment

"Weekly mean pain intensity computed as the arithmetic mean of daily pain intensity values during the week prior to randomization and prior to each study visit. Daily pain intensity is measured on 0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-17.1
Placebo-13.6

Change in Thermal Pain Threshold After 9 Weeks of Treatment

Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain threshold (temperature at which pain is first perceived). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventiondegrees Celsius (Least Squares Mean)
Propranolol ER1.3
Placebo0.5

Change in Thermal Pain Tolerance After 9 Weeks of Treatment

Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain tolerance (temperature at which pain can no longer be tolerated). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventiondegrees Celsius (Least Squares Mean)
Propranolol ER0.5
Placebo0.4

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT LPS Haplotypes

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) Low Pain Sensitive (LPS) haplotypes." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

,
Interventionunits on a scale (Least Squares Mean)
0 LPS haplotypes1 LPS haplotype2 LPS haplotypes
Placebo-12.3-13.2-2.5
Propranolol ER-14.2-12.2-15.2

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT Valine Alleles at rs4680

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) valine alleles at single nucleotide polymorphism (SNP) rs4680." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

,
Interventionunits on a scale (Least Squares Mean)
0 valine alleles1 valine allele2 valine alleles
Placebo-13.9-13.1-9.7
Propranolol ER-14.2-13.9-14.3

Other Studies

3 other studies available for propranolol and Myalgia

ArticleYear
A 62-Year-Old Woman With Diffuse Myalgias, Fatigue, and Shortness of Breath.
    Chest, 2020, Volume: 157, Issue:3

    Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Anticoagulants; Antithyroid Agents; Atrial Fibrill

2020
Effect of Treatment Expectation on Placebo Response and Analgesic Efficacy: A Secondary Aim in a Randomized Clinical Trial.
    JAMA network open, 2020, 04-01, Volume: 3, Issue:4

    Topics: Adolescent; Adult; Aged; Analgesics; Humans; Middle Aged; Myalgia; Placebo Effect; Propranolol; Rand

2020
Effects of a combination of ketanserin and propranolol on inflammatory hyperalgesia in rats.
    European journal of pharmacology, 2013, Dec-05, Volume: 721, Issue:1-3

    Topics: Analgesics; Animals; Arthritis; Carrageenan; Dose-Response Relationship, Drug; Drug Interactions; Hy

2013